Genmab — April 2023
-
We reported that 4 patients with refractory acquired hemophilia A were treated with daratumumab.. All 4 patients achieved varying degrees of remission after daratumumab treatment.. Daratumumab provides a new option for the treatment of refractory acquired hemophilia with good efficacy and safety
. -
-
Det har åbenbart været kendt længe. For eksempel her: https://onlinelibrary.wiley.com/doi/10.1111/hae.14118
-
-
Horizon Therapeutics plc Announces Positive Topline Data from TEPEZZA
(teprotumumab-trbw) Phase 4 Clinical Trial in Patients with Chronic/Low Clinical Activity Score (CAS) Thyroid Eye Disease (TED) https://ir.horizontherapeutics.com/news-releases/news-release-details/horizon-therapeutics-plc-announces-positive-topline-data -
small new trial for Daratumumab in Non-small Cell Lung Cancer With STK11/LKB1 Mutation (not by JNJ) https://clinicaltrials.gov/ct2/show/NCT05807048
-
Investeringspodcasten: Fokus på C25 og sidste udkald for SAS
https://www.proinvestor.com/boards/111969 -
Genmab sidst i udsendelsen.
-
Godmorgen
-
Successful treatment with subcutaneous ofatumumab in an adolescent patient with refractory myelin oligodendrocyte glycoprotein-immunoglobulin G-associated disease (MOGAD) https://www.sciencedirect.com/science/article/pii/S2405650223000199?via%3Dihub
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind